AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting
Four presentations at AAT-AD/PD™ focus meeting
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company, announced today that four new data presentations will be delivered at this year’s AAT-AD/PD™ Focus Meeting, taking place April 2‒5 in Vienna, from the Company’s broad neurodegenerative disease pipeline.